Claims
- 1. A method for the treatment of states of anxiety in a warm blooded mammal which comprises administering to said mammal a therapeutically effective amount of a compound of the general formulae: ##STR16## in which R is hydrogen, alkyl having 1 to 4 carbons, or phenyl alkyl of which the alkyl has one or two carbons, R.sub.1 is hydrogen, alkyl having 1 to 4 carbons or alkenyl of 2 to 4 carbons, R.sub.2 is phenyl, pyridyl, thienyl, or phenyl substituted by one substituent taken from the halogens, alkyl and alkoxy having 1 to 4 carbons, X is fixed in position 5, 6, 7 or 8 on the quinoline ring and represents hydrogen or a halogen, or alkyl having 1 to 4 carbons, and A represents CO or CH.sub.2, or an addition salt thereof with a pharmaceutically acceptable acid.
- 2. The method according to claim 1 in which said compound corresponds to formula (I) wherein R.sub.2 is phenyl or phenyl, substituted by one substituent taken from the halogens and alkyl and alkoxy having 1 to 4 carbon atoms.
- 3. The method according to claim 2 wherein said compound has the formula: ##STR17##
- 4. The method according to claim 1, 2 or 3, wherein said compound is administered by ingestion.
- 5. The method according to claim 1, 2 or 3, wherein said compound is administered by injection.
- 6. A method according to claim 1 in which said compound corresponds to formula (I) wherein X is hydrogen and A is CH.sub.2.
- 7. The method according to claim 1 in which said compound corresponds to formula (I) wherein R.sub.1 is hydrogen.
- 8. The method according to claim 1 in which said compound corresponds to formula (I) wherein R.sub.1 is alkyl containing from 1 to 4 carbon atoms or alkenyl containing 2 to 4 carbon atoms and the compound is in the form of a racemic or enantiomeric diastereoisomer.
- 9. A pharmaceutical composition for the treatment of states of anxiety in a warm blooded mammal which contains, as the pharmacologically active ingredient, a compound of the general formula (I) ##STR18## in which R is hydrogen, alkyl having 1 to 4 carbon atoms or phenylalkyl in which the alkyl has one or two carbons, R.sub.1 is hydrogen, alkyl having 1 to 4 carbons or alkenyl of 2 to 4 carbons, R.sub.2 is phenyl, pyridyl, thienyl, or phenyl substituted by one substituent taken from the halogens, alkyl and alkoxy having 1 to 4 carbons, X is fixed in position 5, 6, 7 or 8 on the quinoline ring and represents hydrogen or a halogen, or alkyl having 1 to 4 carbons, and A represents CO or CH.sub.2, or an addition salt thereof with a pharmaceutically acceptable acid, in a pharmaceutically acceptable non-toxic carrier.
- 10. A pharmaceutical composition according to claim 9 in which the compound used corresponds to formula (I) wherein R.sub.2 is phenyl or phenyl substituted by one substituent taken from the halogens and alkyl and alkoxy containing 1 to 4 carbon atoms.
- 11. A pharmaceutical composition according to claim 9 in which the compound used corresponds to formula (I) wherein X is hydrogen and A is CH.sub.2.
- 12. A pharmaceutical composition according to claim 9 in which the compound used corresponds to formula (I) wherein R.sub.1 is hydrogen.
- 13. A pharmaceutical composition according to claim 9 in which the compound used corresponds to formula (I) wherein R.sub.1 is alkyl having 1 to 4 carbon atoms or alkenyl having 2 to 4 carbon atoms and the compound is in the form of a racemic or enantiomeric diastereoisomer.
- 14. A pharmaceutical composition according to claim 9 in which the compound used is 1-(2-phenyl-4-quinolyl)-2-(4-piperidyl)-ethanone.
- 15. A pharmaceutical composition according to claim 9 in which the compound used is 1-[2-(4-methyl-phenyl)-4-quinolyl]-2-(4-piperidyl)-ethanone.
- 16. A pharmaceutical composition according to claim 9 in which the compound used is 2-[3(R)-ethenyl-4(S)-piperidyl]-1-(2-phenyl-4-quinolyl)-ethanone.
- 17. A pharmaceutical composition according to claim 9 in which the compound used is 2-phenyl-4-[2-(4-piperidyl)-ethyl]-quinoline.
- 18. A pharmaceutical composition according to claim 9 in which the compound used is 2-(4-chloro-phenyl)-4-[2-(4-piperidyl)-ethyl]-quinoline.
- 19. A pharmaceutical composition according to claim 9 in which the compound used is 2-(4-methoxy-phenyl)-4-[2-(4-piperidyl)-ethyl]-quinoline.
- 20. A pharmaceutical composition according to claim 9 in which the compound used is 2-(4-methyl-phenyl)-4-[2-(4-piperidyl)-ethyl]-quinoline.
- 21. A pharmaceutical composition according to claim 9 in which the compound used is 4-2-[1-(2-phenyl-ethyl)-4-piperidyl]-ethyl-2-phenyl-quinoline.
- 22. A pharmaceutical composition according to claim 9 in which the compound used is 4-[2-(1-methyl-4-piperidyl)-ethyl]-2-phenyl-quinoline.
- 23. A pharmaceutical composition according to claim 9 in which the compound used is 2-(2-chloro-phenyl)-4-[2-(4-piperidyl)-ethyl]-quinoline.
Priority Claims (1)
Number |
Date |
Country |
Kind |
79 31396 |
Dec 1979 |
FRX |
|
Parent Case Info
This is a division of application Ser. No. 212,293, filed Dec. 2, 1980, now U.S. Pat. No. 4,433,150 issued Feb. 21, 1984.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4237139 |
Champseix et al. |
Dec 1980 |
|
4402961 |
Dubroeocq |
Sep 1983 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
212293 |
Dec 1980 |
|